DuPont Pharmaceuticals Reveals a Promising R&D Pipeline

Apr 11, 2001, 01:00 ET from DuPont Pharmaceuticals Company

    NEW YORK, April 11 /PRNewswire/ -- DuPont Pharmaceuticals Company, a
 wholly owned subsidiary of DuPont (NYSE:   DD), plans to launch new drugs to
 treat unmet medical needs every 12-18 months beginning in 2004, DuPont
 Pharmaceuticals Chairman and CEO Richard U. De Schutter told a group of
 investment analysts here today.
     "Before I came to DuPont last year my impression of the company's
 pharmaceuticals business was very different from what it is now," said
 Mr. De Schutter who joined DuPont in July 2000 to conduct a strategic
 assessment of DuPont Pharmaceuticals.  "After a closer look, I see a company
 with commercial products that hold strong and sustainable niche positions, a
 remarkable drug discovery capability, and a surprisingly robust pipeline --
 the result of significant investment in R&D that is just beginning to pay
 off."
     Today's meeting focused on DuPont Pharmaceuticals' strong early-to-mid
 stage research and development pipeline, which was presented by Paul A.
 Friedman, MD, President of DuPont Pharmaceuticals Research Laboratories,
 Business Development and Strategic Planning.  The pipeline includes
 21 compounds in development in five therapeutic areas -- Anti-Virals,
 Cardiovascular Diseases, Inflammatory Diseases, Cancer, and Central Nervous
 System Diseases.
     Among the research initiatives highlighted at the meeting were:
     --  a second-generation non-nucleoside reverse transcriptase inhibitor
         (NNRTI) in Phase II for the treatment of HIV - application for
         marketing approval targeted for 2003
     --  a Factor Xa inhibitor in Phase II for the prevention and treatment of
         venous and arterial thrombosis  -- application for marketing approval
         targeted for 2004-2005
     --  a Tumor Necrosis Factor (TNF) Alpha Converting Enzyme (TACE)
         inhibitor in Phase II for rheumatoid arthritis -- application for
         marketing approval targeted for 2004
     --  an integrin-directed radiotherapeutic for the treatment of solid
         cancers in pre-clinical studies -- application for marketing approval
         targeted for 2004-2005
     --  a serotonin (5HT) receptor subtype 2C partial agonist in pre-clinical
         studies for the treatment of obesity -- application for marketing
         approval targeted for 2005-2006
 
     Joseph C. Papa, President and Chief Operating Officer, reviewed the
 company's commercial operations, showing that demand for its major products
 remains strong.  DuPont Pharmaceuticals holds solid competitive positions with
 Sustiva(TM) (efavirenz), a market leading drug to treat HIV; Coumadin(R)
 (warfarin sodium tablets, USP), the most widely prescribed oral anticoagulant
 in the U.S.; and Cardiolite(R) (Kit for the Preparation of Technetium Tc99m
 Sestamibi for Injection), the leading nuclear cardiology imaging agent.
 
     DuPont Pharmaceuticals Company is a worldwide business focused on
 research, development and delivery of pharmaceuticals and imaging agents to
 treat unmet medical needs in the fights against HIV/AIDS, cardiovascular
 disease, inflammatory diseases, cancer and neurological diseases.
     DuPont is a science company, delivering science-based solutions that make
 a difference in people's lives in food and nutrition; health care; apparel;
 home and construction; electronics; and transportation.  Founded in 1802, the
 company operates in 70 countries and has 93,000 employees.
 
     Forward-Looking Statements: This news release contains forward-looking
 statements based on management's current expectations, estimates and
 projections.  All statements that address expectations or projections about
 the future, including statements about the company's strategy for growth,
 product development, market position, expected expenditures and financial
 results are forward-looking statements.  Some of the forward-looking
 statements may be identified by words like "expects," "anticipates," "plans,"
 "intends," "projects," "indicates," and similar expressions.  These statements
 are not guarantees of future performance and involve a number of risks,
 uncertainties and assumptions.  Many factors, including those discussed more
 fully elsewhere in this release and in documents filed with the Securities and
 Exchange Commission by DuPont, particularly its latest annual report on Form
 10-K and quarterly report on Form 10-Q, as well as others, could cause results
 to differ materially from those stated. These factors include, but are not
 limited to changes in the laws, regulations, policies and economic conditions,
 including inflation, interest and foreign currency exchange rates, of
 countries in which the company does business; competitive pressures;
 successful integration of structural changes, including restructuring plans,
 acquisitions, divestitures and alliances; cost of raw materials, research and
 development of new products, including regulatory approval and market
 acceptance; and seasonality of sales of agricultural products.
 
     Note:  The presentations can be monitored via a live audio webcast that
            begins at 1:30 (ET) today.  The webcast, including presentation
            charts, can be accessed via the DuPont home page,
            http://www.dupont.com.  Due to the large number of presentation
            charts, please begin downloading prior to the live webcast.  The
            presentations also will be available after the meeting on DuPont's
            Investor Relations website, www.dupont.com/corp/ir.  Click on
            "Presentations to Analysts."
 
 

SOURCE DuPont Pharmaceuticals Company
    NEW YORK, April 11 /PRNewswire/ -- DuPont Pharmaceuticals Company, a
 wholly owned subsidiary of DuPont (NYSE:   DD), plans to launch new drugs to
 treat unmet medical needs every 12-18 months beginning in 2004, DuPont
 Pharmaceuticals Chairman and CEO Richard U. De Schutter told a group of
 investment analysts here today.
     "Before I came to DuPont last year my impression of the company's
 pharmaceuticals business was very different from what it is now," said
 Mr. De Schutter who joined DuPont in July 2000 to conduct a strategic
 assessment of DuPont Pharmaceuticals.  "After a closer look, I see a company
 with commercial products that hold strong and sustainable niche positions, a
 remarkable drug discovery capability, and a surprisingly robust pipeline --
 the result of significant investment in R&D that is just beginning to pay
 off."
     Today's meeting focused on DuPont Pharmaceuticals' strong early-to-mid
 stage research and development pipeline, which was presented by Paul A.
 Friedman, MD, President of DuPont Pharmaceuticals Research Laboratories,
 Business Development and Strategic Planning.  The pipeline includes
 21 compounds in development in five therapeutic areas -- Anti-Virals,
 Cardiovascular Diseases, Inflammatory Diseases, Cancer, and Central Nervous
 System Diseases.
     Among the research initiatives highlighted at the meeting were:
     --  a second-generation non-nucleoside reverse transcriptase inhibitor
         (NNRTI) in Phase II for the treatment of HIV - application for
         marketing approval targeted for 2003
     --  a Factor Xa inhibitor in Phase II for the prevention and treatment of
         venous and arterial thrombosis  -- application for marketing approval
         targeted for 2004-2005
     --  a Tumor Necrosis Factor (TNF) Alpha Converting Enzyme (TACE)
         inhibitor in Phase II for rheumatoid arthritis -- application for
         marketing approval targeted for 2004
     --  an integrin-directed radiotherapeutic for the treatment of solid
         cancers in pre-clinical studies -- application for marketing approval
         targeted for 2004-2005
     --  a serotonin (5HT) receptor subtype 2C partial agonist in pre-clinical
         studies for the treatment of obesity -- application for marketing
         approval targeted for 2005-2006
 
     Joseph C. Papa, President and Chief Operating Officer, reviewed the
 company's commercial operations, showing that demand for its major products
 remains strong.  DuPont Pharmaceuticals holds solid competitive positions with
 Sustiva(TM) (efavirenz), a market leading drug to treat HIV; Coumadin(R)
 (warfarin sodium tablets, USP), the most widely prescribed oral anticoagulant
 in the U.S.; and Cardiolite(R) (Kit for the Preparation of Technetium Tc99m
 Sestamibi for Injection), the leading nuclear cardiology imaging agent.
 
     DuPont Pharmaceuticals Company is a worldwide business focused on
 research, development and delivery of pharmaceuticals and imaging agents to
 treat unmet medical needs in the fights against HIV/AIDS, cardiovascular
 disease, inflammatory diseases, cancer and neurological diseases.
     DuPont is a science company, delivering science-based solutions that make
 a difference in people's lives in food and nutrition; health care; apparel;
 home and construction; electronics; and transportation.  Founded in 1802, the
 company operates in 70 countries and has 93,000 employees.
 
     Forward-Looking Statements: This news release contains forward-looking
 statements based on management's current expectations, estimates and
 projections.  All statements that address expectations or projections about
 the future, including statements about the company's strategy for growth,
 product development, market position, expected expenditures and financial
 results are forward-looking statements.  Some of the forward-looking
 statements may be identified by words like "expects," "anticipates," "plans,"
 "intends," "projects," "indicates," and similar expressions.  These statements
 are not guarantees of future performance and involve a number of risks,
 uncertainties and assumptions.  Many factors, including those discussed more
 fully elsewhere in this release and in documents filed with the Securities and
 Exchange Commission by DuPont, particularly its latest annual report on Form
 10-K and quarterly report on Form 10-Q, as well as others, could cause results
 to differ materially from those stated. These factors include, but are not
 limited to changes in the laws, regulations, policies and economic conditions,
 including inflation, interest and foreign currency exchange rates, of
 countries in which the company does business; competitive pressures;
 successful integration of structural changes, including restructuring plans,
 acquisitions, divestitures and alliances; cost of raw materials, research and
 development of new products, including regulatory approval and market
 acceptance; and seasonality of sales of agricultural products.
 
     Note:  The presentations can be monitored via a live audio webcast that
            begins at 1:30 (ET) today.  The webcast, including presentation
            charts, can be accessed via the DuPont home page,
            http://www.dupont.com.  Due to the large number of presentation
            charts, please begin downloading prior to the live webcast.  The
            presentations also will be available after the meeting on DuPont's
            Investor Relations website, www.dupont.com/corp/ir.  Click on
            "Presentations to Analysts."
 
 SOURCE  DuPont Pharmaceuticals Company